polyhydroxi
alkaloid
glycosidas
inhibitori
properti
isol
identi
except
discoveri
indolizidin
alkaloid
swainsonin
castanospermin
potent
specic
inhibitori
activ
toward
mannosidas
b
glucosidas
respect
creat
recognit
addit
nitrogen
contain
analogu
simpl
sugar
might
similar
properti
stimul
search
new
member
class
result
natur
occur
member
group
discov
almost
doubl
number
discuss
previou
review
anoth
review
discuss
alkaloid
particular
refer
ecolog
signic
numer
synthet
analogu
prepar
scope
chapter
restrict
chemistri
bioactiv
alkaloid
isol
natur
sourc
glycosidas
inhibitori
properti
consequ
e
ect
glycoprotein
process
alkaloid
glucosidas
inhibitor
discov
conform
singl
structur
class
sever
featur
common
includ
two
hydroxyl
group
nitrogen
atom
gener
heterocycl
charact
small
group
glycosidas
inhibitor
isol
microorgan
also
exist
structur
close
relat
amino
sugar
howev
possibl
integr
major
class
heterocycl
compound
structur
group
base
upon
six
member
ring
may
also
fuse
bicycl
ring
system
five
di
erent
subclass
dene
simpl
monocycl
exampl
complex
bicycl
ring
follow
commonli
use
altern
abbrevi
name
individu
alkaloid
shown
parenthes
alkaloid
pyrrolidin
class
member
ring
exempli
dihydroxi
methyl
dihydroxypyrrolidin
dmdp
r
oh
fulli
tetra
substitut
carbon
atom
ring
posit
trisubstitut
repres
deoxi
dmdp
r
h
dideoxi
imino
arabinitol
r
b
oh
dideoxi
imino
ribitol
r
oh
dihydroxi
hydroxymethyl
pyrrolin
nectrisin
r
b
doubl
bond
n
hydroxyethyl
hydroxymethyl
hydroxypyrrolidin
alkaloid
group
bear
substitu
nitrogen
atom
singl
disubstitut
member
group
known
name
hydroxymethyl
hydroxypyrrolidin
r
h
pentahydroxi
alkaloid
dideoxi
imino
dl
lycero
manno
heptitol
homodmdp
r
ch
oh
apiosid
r
ch
apios
isol
structur
identi
homodmdp
thu
highli
hydroxyl
repres
pyrrolidin
class
alkaloid
six
member
ring
piperidin
class
encompass
nine
member
one
deoxyfagomin
r
h
r
b
oh
disubstitut
two
name
fagomin
r
oh
r
b
oh
epi
fagomin
r
oh
r
oh
trisubstitut
addit
three
alkaloid
deoxynojirimycin
dnj
r
oh
n
methyl
deriv
deoxymannojirimycin
dmj
r
b
oh
tetrasubstitut
latter
also
found
occur
seri
glycosid
name
b
glucopyranosidesand
galactopyranosid
remain
four
alkaloid
character
complet
substitut
carbon
atom
includ
glucos
analogu
nojirimycin
r
oh
r
oh
mannos
analogu
nojirimycin
b
mannojirimycin
r
b
oh
r
oh
galactos
analogu
galactostatin
r
oh
r
b
oh
homonojirimycin
hnj
hydroxymethyl
group
posit
place
hydroxi
group
found
posit
nojirimycin
alkaloid
also
isol
pyrrolizidin
alkaloid
inhibitor
glycosidas
may
regard
formal
structur
sens
result
fusion
two
pyrrolidin
ring
system
common
nitrogen
atom
bridgehead
tetrasubstitut
pyrrolizidin
australin
alexin
di
er
stereochemistri
bridgehead
carbon
atom
c
substitu
ident
congur
certain
amount
confus
arisen
name
epim
compound
bridgehead
congur
ident
australin
classi
epi
alexin
fact
alexin
member
group
isol
date
bridgehead
proton
harri
et
al
propos
alkaloid
r
stereochemistri
name
australin
stereochemistri
alexin
adopt
convent
three
known
natur
occur
epim
would
therefor
name
follow
altern
name
parenthes
epi
australin
di
epi
alexin
oh
epi
australin
di
epi
alexin
ch
oh
epi
australin
di
epi
alexin
oh
b
uniqu
tetrasubstitut
pyrrolizidin
alkaloid
epi
alexaorin
also
r
bridgehead
congur
consist
alkaloid
except
alexin
may
regard
oxid
form
australin
basi
physic
properti
includ
resist
melt
insolubl
solvent
except
water
togeth
evid
carboxyl
ion
infrar
spectrum
alkaloid
shown
exist
zwitterion
form
h
interest
addit
class
casuarin
r
h
highli
oxygen
penta
substitut
pyrrolizidin
alkaloid
also
found
glucosid
r
glucosyl
occurr
sever
australin
alexin
epim
suggest
epimer
form
casuarin
ultim
discov
analog
manner
pyrrolizidin
alkaloid
indolizidin
group
may
visual
pyrrolidin
ring
fuse
piperidin
ring
yield
bicycl
ring
system
seven
natur
occur
member
discov
simplest
dihydroxyl
alkaloid
lentiginosin
r
b
oh
epi
lentiginosin
r
oh
familiar
trihydroxyl
alkaloid
swainsonin
uniqu
within
indolizidin
class
member
r
bridgehead
congur
second
trihydroxyindolizidin
deoxi
epi
castanospermin
r
b
oh
r
h
congur
charac
terist
tetrahydroxi
alkaloid
castanospermin
epim
epi
castanospermin
r
b
oh
r
b
oh
theoret
pentahydroxyl
indolizidin
correspond
casuarin
could
occur
none
yet
isol
natur
sourc
polyhydroxi
pyrrolidin
piperidin
pyrrolizidin
indolizidin
group
estab
lish
time
nortropan
group
rel
new
addit
catalog
alkaloid
class
glycosidas
inhibitori
properti
wherea
tropan
alkaloid
well
known
natur
nortropan
e
compound
nitrogen
atom
methyl
rel
rare
nortropan
ring
system
conceptu
result
fusion
member
pyrrolidin
ring
six
member
piperidin
ring
contrast
indolizidin
fusion
point
nitrogen
atom
monocycl
system
polyhydroxi
nortropan
group
consist
individu
alkaloid
class
chemistri
compound
subject
review
alkaloid
name
calystegin
sourc
rst
member
isol
bindwe
calyst
ia
sepium
consist
featur
calystegin
addit
absenc
n
methyl
presenc
oh
group
bridgehead
junction
c
bicycl
ring
system
e
aminoket
function
three
subclass
dene
name
calystegin
b
c
correspond
tri
tetra
pentahydroxyl
respect
four
trihydroxyl
alkaloid
calystegin
r
oh
r
h
r
h
r
oh
known
although
major
calystegin
bear
equatori
hydroxyl
group
c
posit
latter
two
alkaloid
lack
substitu
calystegin
uniqu
within
subgroup
possess
secondari
hydroxyl
group
member
ring
moieti
calystegin
b
alkaloid
consist
tetrahydroxyl
compound
name
b
b
r
oh
r
oh
b
r
b
oh
r
oh
b
r
oh
r
b
oh
b
calystegin
b
alkaloid
within
subgroup
oh
substitu
although
calystegin
b
b
secondari
hydroxi
group
member
ring
moieti
occur
di
erent
posit
name
c
c
respect
remain
three
member
calystegin
b
b
b
di
er
stereochemistri
hydroxi
group
locat
c
c
six
member
ringth
c
hydroxi
substitu
b
three
alkaloid
alkaloid
name
calystegin
n
correspond
calystegin
b
amino
group
rather
hydroxi
group
bridgehead
c
posit
also
obtain
howev
reaction
nojirimycin
deriv
ammonia
satur
methanol
result
replac
oh
group
nh
substitu
suggest
calystegin
n
artifact
isol
procedur
involv
elut
ion
exchang
column
dilut
ammonium
hydroxid
two
pentahydroxyl
calystegin
c
alkaloid
known
ident
substitut
pattern
includ
hydroxi
group
c
analog
calystegin
b
alkaloid
calystegin
c
r
oh
c
r
b
oh
di
er
stereochemistri
c
hydroxi
substitu
oh
oh
two
addit
alkaloid
bear
axial
orient
methyl
group
nitrogen
atom
isol
structur
character
compound
n
methylcalystegin
b
r
h
n
methylcalystegin
c
r
oh
strictli
classi
tropan
alkaloid
preponder
polyhydroxi
nortropan
isol
date
suggest
new
alkaloid
result
n
methyl
latter
rather
product
normal
biosynthet
rout
tropan
alkaloid
purpos
chapter
therefor
classi
within
nortropan
group
polyhydroxi
alkaloid
glycosidas
inhibitor
isol
primarili
plant
sourc
also
occur
microorgan
occasion
found
insect
sourc
individu
alkaloid
list
tabl
mani
earliest
polyhydroxi
alkaloid
discov
particularli
bicycl
pyrrolizidin
indolizidin
found
plant
famili
legumin
osa
appar
taxonom
relationship
becom
far
less
secur
isol
casuarin
casuarinacea
myrtacea
moreov
swainsonin
identi
constitu
sever
ipomoea
speci
convolvulacea
co
occur
cali
tegin
similarli
initi
isol
calystegin
convolvulacea
overshadow
much
widespread
occurr
solanacea
limit
presenc
moru
speci
moracea
certain
individu
alkaloid
predominantli
dmdp
swainsonin
particularli
wide
spread
pattern
occurr
thu
dmdp
r
oh
isol
plant
famili
aracea
campanulacea
euphorbiacea
hyacinthacea
leguminosa
well
bodi
lepidopteran
urania
ful
en
streptomyc
speci
similarli
swainsonin
also
discov
two
unrel
microorgan
rhizoctonia
le
uminicola
metarhizium
anisoplia
addit
quit
widespread
occurr
plant
shown
biosynthet
pathway
swainsonin
diablo
locowe
astra
alu
oxyphysu
r
le
uminicola
ident
impli
either
direct
indirect
relat
ship
plant
microorgan
thu
genet
abil
produc
alkaloid
could
transfer
one
cours
evolut
altern
microorgan
capabl
produc
alkaloid
may
endophyt
associ
plant
presenc
calystegin
catabol
rhizobium
meliloti
strain
root
calyst
ia
sepium
within
plant
produc
calystegin
emphas
complex
interact
contrast
previou
exampl
castanospermin
epim
australin
alexin
alkaloid
far
restrict
monotyp
castanospermum
austral
speci
alexa
close
relat
genera
leguminosa
appar
exampl
consist
conclus
drawn
regard
distribut
polyhydroxi
alkaloid
present
time
may
natur
product
quit
wide
distribut
mani
new
sourc
discov
futur
compar
new
discoveri
rel
mani
class
alkaloid
probabl
consequ
cryptic
natur
due
except
water
solubl
rel
insolubl
non
hydroxyl
organ
solvent
increas
number
regio
stereochem
potenti
structur
vari
ation
signic
biolog
properti
glycosidas
inhibitor
doubt
result
discoveri
new
member
known
class
ident
nortropan
group
also
indic
new
structur
group
may
yet
remain
discov
hydrophil
polyhydroxi
alkaloid
render
incap
isol
convent
extract
puric
method
involv
extract
nonpolar
organ
kifunensin
kitasatosporia
kifunens
mannosidas
nagstatin
streptomyc
amakusaensi
b
n
acetyl
glucosaminidas
solvent
partit
aqueou
acid
base
ion
exchang
chromatographi
therefor
gener
employ
puric
follow
extract
natur
sourc
water
methanol
ethanol
either
alon
variou
mixtur
subsequ
separ
achiev
paper
column
thin
layer
chromatographi
alkaloid
particularli
amen
detect
thin
layer
chromatographi
associ
specic
spray
reagent
ga
chromatographi
ame
ioniz
mass
spectrometr
detect
glycosidas
inhibitori
properti
techniqu
review
detail
structur
determin
place
particular
relianc
nuclear
magnet
reson
spectroscopi
gener
permit
establish
specic
ring
system
present
substitut
pattern
rel
stereochemistri
hydroxi
group
mass
spectrometri
provid
similar
inform
except
stereochemistri
isol
increas
number
alkaloid
furnish
spectroscop
databas
render
determin
structur
increasingli
facil
determin
absolut
stereochemistri
depend
upon
x
ray
crystallographi
use
whenev
well
rene
crystal
data
obtain
either
alkaloid
crystallin
deriv
hydrochlorid
salt
inhibitori
activ
individu
alkaloid
may
remark
specic
swainsonin
inhibit
mannosidas
golgi
mannosidas
ii
gener
show
spectrum
activ
seri
glycosidas
addit
potenc
may
vari
sourc
particular
enzym
puriti
condit
ph
assay
perform
reason
inhibitori
properti
individu
alkaloid
present
summari
form
tabl
inhibit
n
link
glycoprotein
process
potent
specic
alkaloid
discuss
detail
section
regard
alkaloid
obtain
public
referenc
tabl
earli
approach
correl
structur
polyhydroxi
alkaloid
glycosidas
inhibitori
properti
appear
indic
rather
straightforward
relationship
swainsonin
perceiv
aza
analogu
mannopyranos
lack
hydroxymethin
group
c
otherwis
rel
disposit
remain
hydroxyl
group
therefor
account
abil
inhibit
mannosidas
structur
deoxynojirimycin
r
oh
castanospermin
correl
even
close
monocycl
bicycl
aza
sugar
glucos
inhibit
glucosidas
expect
naiv
approach
reconsid
isol
epi
castanospermin
r
b
oh
r
b
oh
spite
stereochem
similar
mannos
fail
inhibit
either
b
mannosidas
instead
prove
e
ectiv
inhibitor
glucosidas
level
activ
slightli
less
castanospermin
numer
addit
exampl
inhibitori
specic
due
natur
occur
alkaloid
synthet
analogu
undermin
empir
approach
obviou
correl
develop
aid
sophist
molecular
model
techniqu
molecular
orbit
calcul
molecular
model
appli
seri
known
mannosidas
inhibitor
other
expect
inhibit
fail
result
show
good
inhibitor
close
singl
low
energi
conform
mannosyl
cation
demonstr
epi
castanospermin
compli
structur
requir
electroneg
bind
group
present
inhibitor
necessari
specic
activ
establish
littl
signic
addit
studi
type
provid
valuabl
inform
regard
receptor
site
variou
enzym
inhibit
data
avail
compromis
variabl
enzym
condit
measur
made
comprehens
screen
program
use
standard
condit
would
provid
much
use
inform
correl
consequ
design
specic
potent
inhibitor
crystal
structur
glucoamylas
complex
inhibitor
deoxynojirimycin
r
oh
recent
report
structur
data
use
molecular
model
studi
use
deoxynojirimycin
deoxynojirimycin
deriv
dmdp
r
oh
australin
castanospermin
probe
activ
site
enzym
pre
liminari
result
indic
bind
specic
residu
within
activ
site
essenti
inhibitori
activ
inhibitori
potenc
depend
upon
number
hydrogen
bond
involv
bind
howev
although
castanospermin
excel
inhibitor
enzym
lack
requir
therefor
conform
model
nevertheless
approach
illustr
potenti
valu
method
understand
interact
prove
use
increas
renement
model
avail
structur
data
absenc
comprehens
molecular
model
studi
inhibit
result
obtain
ration
basi
gener
accept
model
glycosidas
inhibit
approach
develop
e
ectiv
calystegin
provid
comprehens
seri
structur
relat
natur
polyhydroxi
alkaloid
b
glucosidas
inhibit
model
involv
presenc
two
carboxyl
acid
group
activ
site
enzym
one
respons
gener
stabil
glycosyl
cation
intermedi
specul
calystegin
b
c
r
oh
exo
hydroxi
group
posit
proton
acid
group
respons
catalyt
activ
within
activ
site
analog
manner
inhibitor
conduritol
b
epoxid
contrast
calystegin
b
r
oh
r
oh
show
similar
level
inhibitori
activ
toward
b
glucosidas
suppos
bound
glucosyl
cation
bind
site
hydroxyl
group
posit
essenti
requir
equatori
hydroxyl
group
posit
accord
earlier
studi
interact
inhibitor
b
glucosidas
thu
interact
inhibitori
calystegin
glycosidas
envis
bind
site
determin
specic
catalyt
center
specic
hydroxyl
group
imino
group
mechan
galactosidas
inhibitori
activ
less
appar
calystegin
b
b
c
potent
inhibitor
either
b
galactosidas
yet
calystegin
b
r
b
oh
r
oh
much
closer
congur
similar
galactos
former
inhibitori
activ
enzym
observ
reminisc
situat
epi
castanospermin
indolizidin
alkaloid
seri
obvious
much
larger
set
natur
synthet
epim
enantiom
structur
analogu
need
complet
understand
relationship
appli
predict
inhibitori
activ
progress
direct
made
comparison
glycosidas
inhibit
synthet
analogu
deriv
calystegin
b
nonnatur
enantiom
show
gli
cosidas
inhibitori
properti
wherea
n
methyl
natur
b
suppress
inhibit
b
glucosidas
activ
toward
galactosidas
retain
addit
synthesi
known
natur
occur
alkaloid
purpos
structur
conrmat
mani
epim
enantiom
structur
analogu
prepar
num
ber
synthet
alkaloid
particularli
relat
swainsonin
castanospermin
australin
approach
perhap
exce
isol
natur
sourc
natur
product
focu
review
permit
comprehens
survey
compound
variou
aspect
synthet
approach
either
priori
synthes
rout
commenc
carbohydr
base
templat
summar
number
public
nonnatur
epim
prepar
modic
natur
alkaloid
avail
larg
quantiti
castanospermin
ring
expand
analogu
pyrrolizidin
indolizidin
alkaloid
also
synthes
probabl
least
synthet
compound
especi
epim
known
natur
occur
alkaloid
subsequ
found
occur
natur
addit
new
structur
class
alreadi
gener
might
reason
expect
biosynthes
plant
predomin
among
polyhydroxi
quinolizidin
alkaloid
consist
two
six
member
ring
fuse
bicycl
system
ring
expand
homologu
indolizidin
alkaloid
although
quinolizidin
alkaloid
well
establish
class
natur
product
none
yet
isol
bear
two
hydroxyl
group
probabl
consequ
high
water
solubl
polyhydroxyl
alkaloid
render
unextract
nonhydroxyl
solvent
normal
use
alkaloid
puric
combin
novel
natur
polyhydroxi
alkaloid
togeth
synthet
analogu
tailor
specic
structur
featur
ultim
lead
full
comprehens
interact
alkaloid
receptor
site
enzym
result
glycosidas
inhibitori
properti
might
expect
class
compound
inhibit
glycosidas
consequ
fundament
cellular
function
glycoprotein
process
polyhydroxi
alkaloid
exhibit
except
divers
biolog
activ
discoveri
isol
mani
alkaloid
result
observ
ultim
clinic
e
ect
result
consumpt
anim
plant
contain
bioactiv
compound
predomin
among
exampl
occurr
swainsonin
swainsona
speci
poison
pea
australia
astra
alu
oxytropi
speci
locowe
north
america
potent
mannosidas
inhibitori
activ
swainsonin
disrupt
glycoprotein
process
mannosidas
ii
golgi
result
neuron
vacuol
due
abnorm
storag
mannos
rich
oligosaccharid
lead
neurolog
damag
characterist
locoism
syndrom
howev
clinic
e
ect
limit
nervou
system
sinc
emaci
reproduct
failur
male
femal
congest
right
heart
failur
also
observ
sinc
discoveri
swainsonin
caus
agent
locowe
poison
establish
widespread
phenomenon
addit
occur
renc
report
south
america
mani
part
china
tibet
swainsonin
report
co
occur
calystegin
b
r
oh
r
oh
c
r
oh
ipomoea
speci
australia
caus
poison
sheep
cattl
contrast
exampl
exhibit
complex
e
ect
alkaloid
concentr
chestnut
like
seed
castanospermum
austral
black
bean
primarili
castanospermin
australin
togeth
sever
less
potent
epim
produc
gastrointestin
disturb
livestock
human
discern
neurolog
damag
consist
abil
alkaloid
inhibit
b
glucosidas
result
syndrom
phenotyp
genet
defect
pomp
diseas
although
relationship
directli
establish
eld
case
poison
rodent
feed
experi
castanospermin
result
vacuol
hepatocyt
skelet
myocyt
glycogen
accumul
consist
pomp
diseas
type
ii
glycogenesi
gastrointestin
problem
lethargi
also
observ
livestock
graze
bluebel
hyacinthoid
non
scripta
uk
demonstr
presenc
dmdp
homodmdp
plant
may
account
syndrom
poison
syndrom
rel
obviou
sign
develop
although
may
take
sever
week
consumpt
plant
alkaloid
implic
often
present
low
level
nevertheless
potent
inhibitor
estim
swainsonin
content
dri
weight
plant
may
sucient
induc
locoism
alkaloid
less
activ
present
extrem
low
level
seem
probabl
sign
poison
would
subclin
overt
chang
appar
case
toxic
may
manifest
minor
digest
disturb
failur
gain
weight
deviat
optim
health
could
attribut
stress
infecti
diseas
occurr
variou
calystegin
human
food
plant
famili
solanacea
potato
eggplant
pepper
could
account
varieti
complaint
primarili
gastrointestin
report
certain
individu
consum
veget
anticip
compound
capabl
inhibit
glycosidas
would
inhibitori
e
ect
digest
enzym
defens
herbivor
insect
may
one
role
play
polyhydroxi
alkaloid
plant
contain
convers
well
establish
insect
co
evolv
host
plant
circumv
defens
util
activ
constitu
defens
strategi
involv
specic
alkaloid
demonstr
sever
relationship
castanospermin
ad
artici
diet
highli
inhibitori
feed
pea
aphid
acyrthosiphon
pisum
deterr
level
ppm
consequ
low
surviv
rate
although
alkaloid
inhibit
aphid
trehalas
shown
di
erenti
inhibit
number
disaccharidas
wide
taxonom
distribut
insect
ca
tanospermin
also
shown
antifeed
compound
egyptian
cotton
leafworm
spodoptera
littorali
r
b
oh
dmdp
r
oh
swainsonin
dmdp
also
appear
particularli
e
ectiv
feed
deterr
nymph
locust
schistocerca
aria
locusta
mi
ratoria
level
low
bodi
weight
sinc
alkaloid
inhibit
di
erent
enzym
dicult
correl
antifeed
activ
inhibit
digest
enzym
alon
possibl
deterr
may
also
consequ
block
sensori
respons
glucos
insect
resist
e
ect
alkaloid
observ
thu
bruchid
beetl
callosobruchu
maculatu
feeder
legum
produc
dmdp
gut
glucosidas
time
sensit
alkaloid
ctenocolum
tuberculatum
adapt
feed
exclus
dmdp
contain
speci
legum
subtrib
lonchocarpina
among
lepidoptera
aposemat
color
moth
urania
ful
en
accumul
dmdp
homonojirimycin
food
plant
vine
omphalea
diandra
sequest
alkaloid
present
deoxymannojirimycin
r
b
oh
death
head
hawkmoth
procur
calystegin
solanac
host
mechan
resist
e
ect
alkaloid
understood
appear
like
accumul
serv
protect
role
insect
contrast
alkaloid
may
harm
specic
excret
exampl
pea
aphid
feed
upon
spot
locowe
astra
alu
lenti
inosu
excret
honeydew
swainsonin
acquir
phloem
plant
show
feed
deterr
sinc
plant
colon
opportunist
laboratori
normal
host
pea
aphid
implic
certain
insect
gener
abil
com
partment
elimin
polyhydroxi
alkaloid
might
otherwis
harm
polyhydroxi
alkaloid
sever
structur
class
shown
inhibitori
growth
plant
particularli
noteworthi
respect
castanospermin
demonstr
potent
root
elong
inhibitor
lettuc
lactuca
sativa
alfalfa
medica
sativa
barnyard
grass
echinochloa
cru
alli
red
millet
panicum
miliaceum
alkaloid
much
e
ectiv
dicot
show
inhibit
root
length
growth
ppb
monocot
time
less
sensit
structur
relat
indolizidin
alkaloid
swainsonin
fail
exhibit
phytotox
activ
speci
indic
bioactiv
consequ
b
glucosidas
inhibit
mannosidas
inhibit
nojirimycin
r
oh
r
oh
inhibitori
cell
extens
pisum
sativum
stem
segment
coleoptil
avena
triticum
induc
auxin
consider
evid
elong
consequ
cell
wall
loosen
due
degrad
depolymer
xyloglucan
exo
b
glucanas
inhibit
enzym
alkaloid
could
therefor
account
failur
cell
elong
phytotox
e
ect
polyhydroxi
alkaloid
may
confer
major
competit
advantag
upon
plant
biosynthes
phenomenon
allelopathi
alkaloid
highli
water
solubl
excret
surround
soil
leach
variou
part
plant
suppress
growth
encroach
speci
creation
zone
inhibit
time
movement
water
would
transport
compound
soil
concentr
vicin
secret
plant
attain
level
high
enough
induc
self
inhibit
howev
evid
castanospermum
austral
seed
may
inhibit
germin
presenc
castanospermin
consider
irrig
requir
seed
commenc
sprout
may
valuabl
strategi
nativ
environ
rainfal
highli
season
enabl
germin
root
take
place
raini
season
well
establish
natur
calystegin
b
enantiom
r
oh
r
oh
show
sig
nicant
inhibit
alfalfa
seed
germin
growth
later
product
root
tran
form
robacterium
rhizo
ene
correspond
e
ect
observ
unnatur
enantiom
root
length
reduc
treatment
h
mm
calystegin
b
condit
unnatur
synthet
alkaloid
caus
increas
root
length
result
demonstr
depend
bioactiv
upon
specic
structur
conform
stereochemistri
littl
inform
report
regard
e
ect
polyhydroxi
alkaloid
inhibitor
growth
function
microorgan
although
nojirimycin
r
oh
r
oh
discov
result
antimicrobi
activ
streptomyc
nojiri
roseochromo
ene
lavandula
drug
resist
strain
shi
ellaexneri
antibiot
activ
alkaloid
toward
xanthomona
oryza
render
capabl
prevent
bacteri
leaf
blight
rice
calystegin
rst
isol
root
bindwe
calyst
ia
sepium
although
alkaloid
detect
plant
part
appear
rel
high
abund
subterranean
organ
convolvulacea
solanacea
therefor
believ
nutrit
mediat
plant
associ
rhizospher
bacteria
bacteria
isol
rhizospher
calystegin
produc
plant
capabl
catabol
alkaloid
wherea
bacteria
abil
obtain
plant
elabor
calystegin
addit
wild
type
rhizobium
meliloti
capabl
use
natur
calystegin
b
r
oh
r
oh
exclus
sourc
carbon
nitrogen
wherea
catabol
decient
strain
r
meliloti
furthermor
neither
organ
could
util
unnatur
synthet
enantiom
calystegin
b
abil
catabol
compound
time
may
antibiot
properti
toward
microorgan
obviou
competit
advantag
specic
bacteria
capabl
util
capabl
polyhydroxi
alkaloid
disrupt
gener
cellular
function
glycoprotein
process
lead
expect
compound
therapeut
potenti
treatment
variou
diseas
state
signic
mammalian
toxic
certain
alkaloid
obviou
hindranc
util
howev
frequent
true
mani
drug
candid
unreason
assum
appropri
relationship
could
achiev
moreov
advers
e
ect
neurolog
damag
caus
swainsonin
often
develop
quit
slowli
appear
revers
ingest
alkaloid
termin
would
situat
drug
regimen
investig
alkaloid
therapeut
potenti
far
concentr
three
major
diseas
state
name
treatment
cancer
inhibit
metastasi
antidiabet
drug
antivir
activ
swainsonin
receiv
particular
attent
antimetastat
agent
vivo
experi
mice
shown
pulmonari
colon
reduc
anim
provid
drink
water
contain
mg
ml
swainsonin
h
prior
inject
murin
melanoma
cell
e
ect
shown
due
enhanc
natur
killer
cell
increas
suscept
cancer
cell
e
ect
pharmacokinet
swainsonin
experi
indic
level
alkaloid
period
administr
would
sucient
produc
neurolog
damag
suggest
post
oper
metastasi
tumor
cell
human
could
suppress
intraven
administr
alkaloid
prior
follow
surgeri
clinic
trial
human
advanc
malig
nanci
show
lysosom
mannosidas
golgi
mannosidas
ii
inhibit
improv
clinic
statu
occur
castanospermin
also
report
suppress
metastasi
mice
experi
alkaloid
extens
swainsonin
castanospermin
deoxynojirimycin
r
oh
shown
capabl
suppress
infect
number
retro
virus
includ
human
immunodeci
viru
hiv
respons
aid
e
ect
consequ
inhibit
glycoprotein
process
result
chang
structur
glycoprotein
coat
viru
cellular
recognit
host
thu
prevent
syncytium
format
suppress
spite
signic
e
ect
alkaloid
su
er
disadvantag
highli
water
solubl
therefor
excret
rapidli
defect
overcom
derivat
give
butyryl
castanospermin
n
butyl
deoxynojirimycin
compound
undergon
clinic
trial
aid
human
either
alon
combin
azt
might
expect
gastrointestin
disturb
report
signic
side
e
ect
anoth
structur
modic
deoxynojirimycin
n
hydroxyethyl
deriv
miglitol
inhibitor
glucosidas
clinic
evalu
releas
antidiabet
drug
insulin
noninsulin
depend
diabet
alkaloid
shown
potent
inhibit
glucos
induc
insulin
releas
also
suppress
islet
glucosid
hydrolas
activ
thu
control
postprandi
glycemia
structur
relat
alkaloid
galactopyranosyl
dnj
fagomin
also
shown
antihypoglycem
activ
streptozocin
induc
diabet
mice
test
human
abil
polyhydroxi
alkaloid
glycosidas
inhibitor
prevent
cellular
recognit
result
evalu
clinic
situat
suppress
immun
respons
would
desir
use
parasit
diseas
thu
vivo
experi
shown
castanospermin
use
immunosuppress
drug
promot
heart
renal
allograft
surviv
rat
parasit
diseas
may
also
control
alter
cellular
recognit
process
castanospermin
provid
protect
cerebr
malaria
prevent
adhes
plasmo
dium
falciparum
infect
erythrocyt
swainsonin
inhibit
associ
trypano
soma
cruzi
caus
agent
chaga
diseas
host
cell
format
defect
mannos
rich
oligosaccharid
cell
surfac
doubt
polyhydroxi
alkaloid
consider
potenti
treatment
varieti
diseas
state
human
anim
primari
challeng
introduc
commerci
drug
minim
toxic
enhanc
specic
beneci
e
ect
improv
pharmacokinet
properti
result
much
lower
dose
rate
necessari
undesir
side
e
ect
limit
increas
specic
action
achiev
prepar
synthet
deriv
comprehens
understand
relationship
glycoprotein
widespread
natur
found
eucaryot
cell
also
shown
present
variou
archaebacteria
well
lower
bacteria
addit
becom
emin
clear
carbohydr
sequenc
glycoprotein
glycolipid
proteoglycan
critic
import
ligand
molecular
recognit
least
regard
n
link
glycoprotein
review
focus
molecul
implic
number
import
physiolog
function
especi
recognit
reac
tion
involv
critic
phenomena
inamm
pathogenesi
parasit
devel
opment
cell
adhes
symbiosi
mention
n
link
oligosaccharid
also
involv
lysosom
enzym
target
uptak
remov
glycoprotein
blood
protein
fold
endoplasm
reticulum
mani
physiolog
phenomena
potenti
signic
although
carbohydr
portion
glycoprotein
shown
particip
everi
case
recognit
specic
oligosaccharid
structur
clearli
central
mani
case
thu
inhibitor
block
specic
step
assembl
variou
n
link
oligosaccharid
caus
format
alter
immatur
oligosaccharid
structur
valuabl
tool
probe
role
carbohydr
glycoprotein
function
figur
show
three
repres
structur
n
link
oligosaccharid
oligosaccharid
core
structur
shown
within
box
compos
branch
trimannos
structur
link
disaccharid
glcnac
e
nn
diacetylchitobios
imma
ture
initi
synthes
oligosaccharid
high
mannos
structur
shown
oligosaccharid
biosynthet
precursor
give
rise
n
link
oligo
saccharid
high
mannos
oligomannos
type
oligosaccharid
commonli
found
glycoprotein
lower
eucaryot
fungi
yeast
although
small
percentag
n
link
oligosaccharid
anim
cell
surfac
protein
high
mannos
type
lower
structur
c
figur
hybrid
type
oligosaccharid
produc
partial
process
glcnac
transferas
step
addit
variou
sugar
link
mannos
branch
howev
hybrid
structur
appar
result
absenc
mannosidas
ii
action
activ
clear
whether
hybrid
structur
form
normal
found
glycoprotein
produc
individu
hempa
diseas
condit
individu
lack
mannosidas
ii
activ
hybrid
structur
also
induc
treat
cultur
cell
swainsonin
middl
structur
b
figur
exampl
one
type
complex
oligosaccharid
frequent
found
cell
surfac
glycoprotein
higher
eucaryot
low
densiti
lipoprotein
receptor
mani
membran
receptor
particular
structur
refer
biantennari
complex
chain
complex
oligosaccharid
may
three
sialic
acid
galactos
glcnac
chain
triantennari
chain
four
trisaccharid
sequenc
tetraantennari
chain
biosynthesi
n
link
oligosaccharid
chain
involv
two
rather
distinct
seri
reaction
rst
pathway
give
rise
precursor
immatur
oligosaccharid
transfer
cotransl
protein
chain
synthes
membran
bound
polysom
contrast
second
seri
reaction
involv
modic
precursor
oligosaccharid
remov
sugar
addit
other
give
larg
number
di
erent
oligosaccharid
structur
rst
pathway
requir
particip
lipid
carrier
involv
lipid
link
saccharid
intermedi
reaction
lead
product
nal
lipid
link
oligosaccharid
precursor
present
figur
figur
biosynthet
assembl
core
n
link
oligosaccharid
shown
figur
assembl
n
link
oligosaccharid
chain
initi
endoplasm
reticulum
er
transfer
glcnac
p
udp
glcnac
dolichyl
p
form
glcnac
pp
dolichol
second
glcnac
ad
also
udp
glcnac
produc
pp
dolichol
mannos
residu
ad
rst
linkag
termin
glcnac
next
four
linkag
form
import
intermedi
man
glcnac
pp
dolichol
rst
seven
reaction
believ
occur
cytosol
side
er
membran
sinc
involv
nucleosid
diphosph
sugar
sugar
donor
activ
sugar
donor
biosynthes
cytoplasm
solubl
sugar
nucleotid
pyrophosphorylas
seem
like
therefor
sugar
acceptor
dolichyl
p
initi
ori
ent
er
membran
way
phosphat
group
expos
cytoplasm
therefor
abl
accept
sugar
cytosol
addit
rst
seven
sugar
give
man
glcnac
pp
dolichol
lipid
link
oligosaccharid
believ
undergo
ip
op
membran
oligosaccharid
chain
becom
orient
toward
lumen
er
assembl
oligosaccharid
complet
addit
four
mannos
residu
three
glucos
unit
give
glc
man
glcnac
pp
dolichol
last
seven
sugar
e
four
mannos
three
glucos
unit
ad
lumen
er
donat
activ
lipid
precursor
mannosyl
p
dolichol
glucosyl
p
dolichol
two
sugar
donor
synthes
use
sugar
nucleotid
gdp
mannos
udp
glucos
transfer
respect
sugar
dolichyl
p
reaction
synthesi
activ
lipid
link
monosaccharid
propos
occur
cytosol
side
er
membran
catalyz
enzym
dol
p
man
synthas
dol
p
glc
synthas
nal
step
pathway
transfer
glc
man
glcnac
lipid
carrier
specic
asparagin
residu
polysom
bound
protein
catalyz
enzym
oligo
saccharyltransferas
asparagin
residu
act
acceptor
oligosaccharid
chain
must
tripeptid
consensu
sequenc
asn
x
ser
thr
x
amino
acid
except
prolin
certain
amino
acid
favor
other
addit
tripeptid
sequenc
must
specic
conform
orient
b
turn
protein
order
glycosyl
spite
fact
reaction
pathway
well
known
still
clear
pathway
regul
control
point
locat
oligosaccharid
transfer
protein
protein
chain
still
synthes
er
oligosaccharid
begin
undergo
number
process
trim
reaction
initi
reaction
second
pathway
encompass
remov
three
glucos
residu
six
mannos
residu
later
process
reaction
involv
addit
number
sugar
princip
glcnac
galactos
neuramin
acid
l
fucos
possibl
galnac
process
pathway
outlin
figur
rst
process
step
involv
membran
bound
glucosidas
call
glucosidas
remov
outermost
link
glucos
enzym
quit
distinct
common
glycosidas
lysosom
enzym
involv
degrad
polysaccharid
glycolipid
complex
carbohydr
sinc
enzym
usual
ph
optimum
around
wherea
glucosidas
ph
optimum
addit
common
glycosidas
specic
sugar
nonreduc
terminu
anomer
con
gurat
glycosid
bond
strong
specic
group
sugar
attach
specic
glycosid
linkag
group
anoth
sugar
glucosidas
hand
cleav
termin
glucos
attach
linkag
anoth
glucos
thu
glucosidas
work
p
nitrophenyl
glucopyranosid
final
kind
enzym
distinguish
locationth
process
glucosidas
er
hydrolyt
glucosidas
usual
lysosom
glucosidas
enzym
initi
trim
matur
n
link
oligo
saccharid
chain
therefor
may
play
key
role
control
rate
transport
exit
newli
form
glycoprotein
er
golgi
apparatu
enzym
puri
number
sourc
includ
calf
porcin
liver
bovin
mammari
gland
well
plant
mung
bean
seedl
yeast
saccharomyc
cerevisia
pig
liver
glu
cosidas
clone
human
hippocampu
cdna
librari
express
co
cell
express
enzym
molecular
mass
kda
degrad
endoglucosaminidas
h
endo
h
kda
form
indic
enzym
high
mannos
oligosaccharid
asparagin
glycosyl
site
hydrophob
prole
enzym
fact
trypsin
treatment
microsom
releas
kda
fragment
support
view
glucosidas
transmembran
glycoprotein
contain
short
cytoplasm
domain
amino
acid
follow
transmembran
domain
larg
c
termin
catalyt
domain
lumin
side
er
membran
yeast
mutant
isol
lack
glucosidas
produc
glycoprotein
glc
man
glcnac
structur
alter
normal
structur
oligosaccharid
yeast
protein
e
ect
secret
cho
mutant
miss
glucosidas
also
isol
virtu
resist
toxic
e
ect
lectin
l
pha
mutat
cell
call
lec
profound
e
ect
secret
target
glycoprotein
second
glucosidas
locat
lumen
er
call
glucosidas
ii
remov
two
link
glucos
give
man
glcnac
protein
interestingli
enzym
remov
outermost
link
glucos
quit
rapidli
min
wherea
remov
innermost
link
glucos
consider
slower
min
earlier
observ
activ
enzym
correl
well
recent
describ
role
enzym
protein
fold
singl
link
glucos
high
mannos
chain
function
recognit
site
bind
chaperon
protein
improperli
fold
denatur
chaperon
expedit
assist
proper
fold
thu
shown
er
contain
protein
call
calnexin
function
help
newli
synthes
membran
protein
fold
proper
conform
step
appar
necessari
mani
protein
transport
golgi
apparatu
proper
rate
calnexin
lectin
recogn
singl
link
glucos
high
mannos
chain
unfold
denatur
protein
sinc
glucosidas
ii
act
fairli
slowli
nal
link
glucos
must
time
period
glycoprotein
singl
glucos
oligosaccharid
glucos
high
mannos
chain
unfold
protein
recognit
site
calnexin
bind
protein
yet
assum
proper
conform
er
also
contain
safeti
mechan
assur
unfold
improperli
fold
glyco
protein
interact
chaperon
obtain
conform
requir
exit
er
golgi
apparatu
thu
unusu
glucosyltransferas
local
er
function
transfer
glucos
udp
glucos
high
mannos
chain
denatur
nativ
glycoprotein
glucos
ad
calnexin
recogn
assist
protein
proper
fold
transfer
golgi
result
glycoprotein
three
glucos
residu
remov
glucosidas
ii
fail
fold
proper
conform
reglucosyl
novel
enzym
signal
allow
protein
anoth
opportun
interact
calnexin
fold
properli
mechan
involv
remov
glucos
glucosidas
reglucosyl
glucosyltransferas
postul
part
uniqu
glycoprotein
specic
fold
qualiti
control
mechan
er
allow
organel
control
pass
properli
fold
glycoprotein
next
step
transport
process
glucosidas
ii
fairli
high
ph
optimum
also
hydrolyz
p
nitrophenyl
glucosid
hand
enzym
appear
fairli
specic
link
glucos
sinc
hydrolysi
glc
man
glcnac
inhibit
nigeros
link
disaccharid
glucos
correspond
link
disaccharid
glucos
enzym
pig
kidney
shown
subunit
molecular
mass
kda
contain
high
mannos
oligosaccharid
enzym
mung
bean
seedl
two
kda
subunit
well
high
mannos
oligosaccharid
although
anim
system
glucosidas
ii
subunit
report
molecular
mass
kda
enzym
report
locat
rough
smooth
er
pig
hepatocyt
also
locat
post
golgi
structur
tubular
cell
pig
kidney
cdna
glucosidas
ii
clone
use
degener
oligonucleotid
base
amino
acid
sequenc
deriv
puri
pig
liver
glucosidas
ii
kb
cdna
isol
open
read
frame
kb
amino
acid
sequenc
contain
known
er
retent
signal
hydrophob
region
might
repres
transmembran
domain
contain
singl
n
link
oligosaccharid
consensu
site
near
amino
terminu
process
glucosidas
best
assay
vitro
use
radiolabel
oligosaccharid
substrat
man
glcnac
man
glcnac
substrat
readili
prepar
cultur
anim
cell
infect
envelop
viru
inuenza
viru
n
link
glycoprotein
coat
thu
mdck
cell
infect
inuenza
viru
progeni
viru
produc
cell
presenc
glucosidas
mannosidas
process
inhibitor
prevent
remov
specic
sugar
exampl
viru
grown
presenc
castanospermin
oligosaccharid
chain
envelop
glycoprotein
mostli
glc
man
glcnac
structur
wherea
viru
grown
presenc
deoxymannojirimycin
r
b
oh
kifunensin
would
mostli
man
glcnac
structur
oligo
saccharid
radiolabel
grow
viru
presenc
either
label
three
glucos
residu
oligosaccharid
label
nine
mannos
unit
viru
infect
mdck
cell
incub
h
allow
viru
replic
lyse
cell
viru
particl
isol
cultur
medium
ultracentrifug
viral
pellet
treat
exhaust
pronas
digest
protein
result
glycopeptid
isol
gel
ltration
glycopeptid
incub
endo
h
e
endo
glucosaminidas
h
cleav
high
mannos
glucos
contain
high
mannos
glyco
peptid
result
oligosaccharid
singl
glcnac
reduc
end
isol
gel
ltration
column
biogel
p
two
glucosidas
remov
three
glucos
n
link
oligosaccharid
shown
figur
number
mannosidas
remov
one
four
link
mannos
residu
ultim
give
man
glcnac
protein
e
protein
believ
least
three
di
erent
mannosidas
involv
convers
man
glcnac
man
glcnac
n
er
mannosidas
golgi
man
mannosidas
golgi
mannosidas
enzym
di
er
number
properti
includ
substrat
specic
sensit
variou
mannosidas
inhibitor
intracellular
locat
er
mannosidas
presum
remov
singl
mannos
gener
uniqu
specic
man
glcnac
structur
enzym
report
cleav
mannosid
linkag
man
glcnac
normal
resist
hydrolysi
golgi
man
mannosidas
howev
solubl
form
er
mannosidas
shown
exhibit
rather
low
specic
releas
sever
di
erent
link
mannos
residu
man
glcnac
substrat
mannos
remov
random
fashion
three
di
erent
man
glcnac
structur
produc
well
number
man
glcnac
isom
discrep
specic
er
mannosidas
solubl
mannosidas
report
two
studi
may
due
e
ect
protein
substrat
specic
e
er
mannosidas
may
act
di
erent
specic
free
oligosaccharid
compar
protein
bound
oligosaccharid
man
mannosidas
least
enzym
pig
liver
cleav
free
peptid
bound
man
glcnac
give
specic
man
glcnac
isom
thu
er
mannosidas
man
mannosidas
may
complementari
anoth
mannosidas
isol
rat
liver
golgi
requir
ca
appar
cleav
four
mannos
man
glcnac
compar
rate
indic
alon
could
produc
man
glcnac
involv
format
complex
type
oligosaccharid
exact
function
di
erent
mannosidas
current
known
fact
enzym
remov
linkag
consider
redund
action
indic
specic
role
process
perhap
target
pathway
may
function
produc
oligosaccharid
specic
signal
particular
role
cell
addit
exo
mannosidas
anim
cell
tissu
contain
endo
mannosidas
cleav
glucos
branch
glc
man
glcnac
two
termin
mannos
releas
glc
man
glc
man
glc
man
oligosaccharid
leav
man
glcnac
protein
enzym
presum
prefer
oligosaccharid
singl
glucos
high
mannos
chain
may
repres
altern
rout
util
glucosidas
glucosidas
ii
nevertheless
specic
role
interest
enzym
process
pathway
still
clearit
may
repres
new
target
rout
cell
cdna
encod
endoplasm
reticulum
mannosidas
isol
rat
liver
librari
two
degener
oligonucleotid
prepar
base
amino
acid
sequenc
obtain
puri
enzym
oligonucleotid
use
primer
pcr
liver
cdna
templat
gener
unambigu
cdna
probe
base
pair
cdna
fragment
use
isol
cdna
clone
hybrid
two
overlap
clone
use
construct
full
length
cdna
base
encod
open
read
frame
amino
acid
kda
protein
contain
six
known
peptid
sequenc
signal
sequenc
membran
span
domain
found
amino
acid
sequenc
northern
blot
variou
anim
tissu
use
cdna
probe
reveal
kb
mrna
present
tissu
examin
enrich
adren
gland
testi
less
abund
spleen
intestin
muscl
rat
liver
er
mannosidas
bear
strike
homolog
vacuolar
mannosidas
saccharomyc
cerevisia
man
mannosidas
also
clone
use
mix
pig
liver
cdna
librari
three
isol
clone
allow
construct
base
pair
full
length
cdna
cdna
construct
contain
open
read
frame
bp
encod
kda
protein
amino
acid
kda
activ
enzym
express
co
cell
substrat
specic
sensit
inhibitor
metal
ion
requir
previous
isol
kda
activ
fragment
structur
hydrophob
analysi
code
region
well
studi
indic
enzym
nonglycosyl
type
ii
transmembran
protein
residu
cytosol
tail
follow
amino
acid
membran
anchor
lumin
residu
stem
kda
c
termin
catalyt
domain
immunouoresc
studi
indict
pig
liver
enzym
express
co
cell
resid
er
hand
human
kidney
enzym
express
co
cell
local
golgi
apparatu
author
specul
local
like
sequenc
depend
remov
four
link
mannos
unit
man
glcnac
protein
substrat
glcnac
transferas
glycosyltransferas
medial
golgi
stack
transfer
glcnac
udp
glcnac
mannos
branch
give
glcnac
man
glcnac
protein
enzym
puri
homogen
variou
sourc
shown
type
ii
integr
membran
protein
enzym
specic
arm
n
glycan
core
transfer
glcnac
linkag
termin
link
mannos
reaction
necessari
mannosidas
ii
remov
mannos
arm
give
trimannos
structur
gene
enzym
disrupt
homolog
recombin
embryon
stem
cell
transmit
germ
line
mice
lack
glcnac
transferas
activ
surviv
term
biochem
morpholog
analysi
embryo
show
development
retard
especi
regard
neural
tissu
glcnac
ad
link
mannos
mannosidas
ii
remov
two
mannos
link
link
mannos
branch
result
reaction
protein
mannosidas
ii
puri
homogen
rat
liver
mung
bean
seedl
anim
enzym
plant
enzym
appar
molecular
mass
kda
sd
gel
enzym
appear
glycoprotein
howev
primari
sequenc
murin
mannosidas
ii
deriv
clone
studi
predict
molecular
mass
kda
deglycosyl
enzym
discrep
may
explain
anomal
migrat
sd
page
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
deglycosyl
glycosyl
protein
sinc
glycosyl
enzym
migrat
kda
protein
full
length
mannosidas
ii
cdna
isol
cdna
librari
murin
enzym
type
ii
transmembran
glycoprotein
cytoplasm
tail
amino
acid
singl
transmembran
domain
lumin
orient
catalyt
domain
cdna
overexpress
co
cell
result
appear
immunoreact
materi
perinuclear
membran
array
indic
golgi
local
human
mannosidas
cdna
also
isol
gene
map
chromosom
although
enzym
locat
golgi
apparatu
subgolgi
locat
depend
cell
type
thu
exocrin
pancreat
cell
hepatocyt
intestin
goblet
cell
enzym
found
medial
tran
golgi
cho
cell
restrict
medial
golgi
thu
cell
mannosidas
mannosidas
ii
appear
coloc
region
golgi
mannosidas
ii
activ
demonstr
mammalian
tissu
examin
howev
level
enzym
low
brain
interestingli
enough
tissu
found
altern
hydrolyt
enzym
mannosidas
activ
cleav
man
glcnac
man
glcnac
enzym
clearli
distinct
mannosidas
ii
term
substrat
specic
reaction
variou
mannosidas
inhibitor
see
section
specic
role
glycoprotein
process
still
determin
lack
mannosidas
ii
also
observ
hempa
diseas
hereditari
aiction
character
alter
express
one
sever
glycoprotein
process
enzym
one
form
diseas
result
decienc
mrna
express
mannosidas
ii
lymphocyt
deriv
patient
defect
contain
less
control
mannosidas
ii
level
glycoprotein
contain
mostli
hybrid
type
oligosaccharid
catalyt
domain
murin
mannosidas
ii
cdna
show
consider
amount
similar
sequenc
lysom
mannosidas
clone
slime
mold
dictyostelium
discoideum
nevertheless
two
enzym
consider
di
erenc
ph
optimum
sub
strate
specic
local
within
cell
base
sequenc
similar
propos
two
enzym
deriv
duplic
diverg
primordi
mannosidas
gene
later
acquisit
local
inform
substrat
specic
lesser
degre
sequenc
similar
observ
murin
mannosidas
ii
endoplasm
reticulum
mannosidas
cytoplasm
homologu
yeast
vacuolar
mannosidas
follow
action
variou
glycosidas
trim
part
pathway
number
glycosyltransferas
act
glcnacman
glcnac
protein
produc
complex
type
n
link
oligosaccharid
thu
tran
golgi
apparatu
number
glcnac
transferas
galactosyltransferas
fucosyltransferas
sialyltransferas
add
sugar
n
link
chain
give
great
divers
complex
chain
biantennari
triantennari
tetraantennari
structur
mani
enzym
well
character
number
gene
import
protein
clone
although
good
inhibitor
enzym
current
avail
search
chemic
synthesi
compound
reward
futur
goal
number
low
molecular
mass
compound
isol
natur
sourc
synthes
chemic
specic
inhibit
glycosidas
trim
pathway
inhibitor
becom
valuabl
tool
use
biolog
system
determin
role
n
link
oligosaccharid
process
function
variou
membran
secretori
glycoprotein
inhibitor
special
interest
sinc
small
molecul
abl
permeat
cell
therefor
use
intact
cell
tissu
studi
vivo
situat
addit
inhibitor
use
distinguish
variou
process
enzym
best
exampl
shown
tabl
clear
mani
di
erent
mannosidas
di
erent
sensit
variou
mannosidas
inhibitor
remain
section
chapter
describ
chemistri
biolog
activ
variou
class
alkaloid
alkaloid
like
compound
function
inhibitor
n
link
oligosaccharid
process
number
natur
occur
sugar
like
compound
ring
oxygen
replac
nitrogen
isol
describ
section
mani
alkaloid
shown
potent
inhibitor
variou
glycosidas
nitrogen
ring
appar
mimic
catalyt
intermedi
reaction
e
oxycarbanion
intermedi
compound
still
specic
recogn
bound
activ
site
particular
glycosidas
resembl
chiral
specic
sugar
like
glucos
mannos
thu
function
valuabl
inhibitor
glycosidas
involv
glycoprotein
process
castanospermin
indic
earlier
indolizidin
alkaloid
rst
isol
seed
australian
tree
castanospermum
austral
initi
studi
e
ect
compound
biolog
system
demonstr
reason
potent
inhibitor
b
glucosidas
later
studi
also
show
castanospermin
inhibit
number
isol
glucosidas
includ
glycoprotein
process
enzym
glucosidas
glucosidas
ii
sucras
maltas
lysosom
glucosidas
sinc
compound
potent
inhibitor
intestin
maltas
sucros
prevent
degrad
disaccharid
sucros
maltos
therefor
block
normal
digest
starch
sucros
result
seed
ca
tanospermum
austral
toxic
anim
caus
sever
diarrhea
gastrointestin
upset
addit
castanospermin
fed
mice
four
day
period
inhibit
lysosom
glucosidas
caus
accumul
partial
degrad
glycogen
particl
within
lysosom
e
situat
similar
occur
pomp
diseas
genet
diseas
aict
individu
lack
lysosom
glucosidas
variou
cultur
anim
cell
grown
presenc
castanospermin
process
n
link
oligosaccharid
block
rst
step
e
glucosidas
asparagin
link
glycoprotein
mostli
oligosaccharid
glc
man
glcnac
structur
howev
cell
endomannosidas
golgi
releas
glc
glucos
contain
n
link
oligosaccharid
although
enzym
prefer
act
mono
glucosyl
oligosaccharid
releas
disaccharid
appar
also
cleav
oligosaccharid
contain
three
glucos
residu
thu
cell
contain
enzym
may
abl
get
around
castanospermin
block
mention
role
endomannosidas
glycoprotein
process
yet
understood
glucosidas
inhibitor
act
level
glucosidas
similar
e
ect
castanospermin
may
somewhat
di
erent
level
activ
di
erent
specic
includ
deoxynojirimycin
r
oh
polyhydroxyl
pip
eridin
analogu
correspond
glucopyranos
nitrogen
ring
compound
also
inhibit
b
glucosidas
anoth
inhibitor
pyrrolidin
alkaloid
dihydroxi
methyl
dihydroxypyrrolidin
dmdp
r
oh
latter
compound
much
less
e
ec
tive
two
inhibitor
suggest
six
member
ring
structur
prefer
inhibitori
activ
nevertheless
dmdp
inhibit
b
glucosidas
e
ect
prevent
remov
glucos
residu
n
link
oligosaccharid
target
glycoprotein
quit
dramat
thu
hepatocyt
cell
line
hep
incub
variou
time
presenc
deoxynojirimycin
rate
secret
serum
protein
antitrypsin
greatli
diminish
rate
secret
serum
n
link
glycoprotein
ceruloplasmin
c
compon
complement
margin
ect
cell
fraction
studi
indic
antitrypsin
accumu
late
held
compart
suggest
presenc
glucos
oligosaccharid
might
retard
movement
protein
er
golgi
apparatu
similar
result
obtain
biosynthesi
target
low
densiti
lipoprotein
receptor
broblast
smooth
muscl
cell
examin
absenc
presenc
castanospermin
studi
could
shown
cell
grown
presenc
inhibitor
one
half
number
receptor
molecul
cell
surfac
therefor
bound
much
less
ldl
howev
inhibit
cell
still
total
number
ldl
receptor
molecul
cell
miss
receptor
molecul
found
locat
er
golgi
base
cell
fraction
studi
interest
studi
done
im
lymphocyt
castanospermin
use
examin
role
oligosaccharid
process
biosynthesi
target
insulin
receptor
cell
treat
castanospermin
decreas
number
insulin
receptor
cell
surfac
demonstr
bind
insulin
studi
show
remov
glucos
residu
n
link
glycoprotein
necessari
cleavag
insulin
proreceptor
matur
receptor
howev
shown
system
presenc
glucos
appar
slow
transport
glycoprotein
er
golgi
result
decreas
number
receptor
molecul
cell
surfac
case
e
glycoprotein
coronaviru
castanospermin
deoxynojirimycin
caus
signic
drop
format
viru
also
dramat
inhibit
appear
e
glycoprotein
cell
surfac
signicantli
e
form
presenc
glucosidas
inhibitor
still
acyl
fatti
acid
control
viral
e
howev
drug
induc
e
accumul
intracellular
compart
denit
identi
probabl
er
anoth
studi
deal
sodium
channel
rat
brain
neuron
also
show
addit
palmit
acid
protein
prevent
process
inhibitor
sodium
channel
compos
b
subunit
form
complex
matur
channel
subunit
undergo
post
translat
modic
addit
palmit
incorpor
fatti
acid
glycoprotein
prevent
tunicamycin
glycosyl
inhibitor
complet
prevent
format
n
link
oligosaccharid
hand
castanospermin
prevent
process
oligosaccharid
chain
addit
sialic
acid
e
ect
addit
palmit
acid
alkaloid
also
ect
coval
assembl
b
subunit
biolog
function
channel
thu
oligo
saccharid
appar
necessari
palmit
addit
specic
structur
oligo
saccharid
e
high
mannos
complex
presum
critic
addit
palmit
group
envelop
protein
hiv
aid
associ
viru
protein
glycoprotein
mani
oligosaccharid
chain
oligosaccharid
involv
recognit
mechan
attach
hiv
receptor
lymphocyt
suscept
cell
interact
target
molecul
suscept
cell
caus
fusion
cell
format
syncytia
necessari
viral
format
infect
glucosidas
inhibitor
deoxynojirimycin
dnj
castanospermin
caus
signic
decreas
format
new
viru
syncytium
format
result
interest
result
inhibitor
test
human
clinic
trial
potenti
antiaid
drug
although
result
publish
one
report
side
e
ect
human
occurr
diarrhea
gastrointestin
problem
individu
take
compound
shown
tabl
number
compound
addit
castanospermin
dnj
also
inhibitor
glucosidas
glycoprotein
process
one
compound
pyrrolidin
alkaloid
dmdp
r
oh
occur
sever
di
erent
plant
famili
place
medium
cultur
anim
cell
dmdp
inhibit
step
give
oligosaccharid
structur
e
glc
man
glcnac
castanospermin
dnj
howev
dmdp
much
less
e
ectiv
inhibitor
therefor
consider
higher
concentr
necessari
medium
fact
member
ring
structur
show
glycosidas
activ
enzym
act
hexopyranosid
signic
would
certainli
warrant
model
studi
structur
comparison
indolizidin
piperidin
alkaloid
sever
unusu
structur
show
increas
select
toward
two
process
glucosidas
e
glucosidas
glucosidas
ii
discuss
australin
tetrahydroxypyrrolizidin
alkaloid
found
seed
contain
castanospermin
name
castanospermum
austral
howev
australin
present
seed
much
lower
amount
castanospermin
compound
good
inhibitor
fungal
amyloglucosidas
also
inhibit
process
glucosidas
howev
contrast
glucosidas
inhibitor
discuss
also
fairli
e
ectiv
glucosidas
ii
australin
poor
inhibitor
glucosidas
ii
thu
australin
rst
glucosidas
inhibitor
distinguish
two
process
enzym
nevertheless
key
ect
australin
cell
cultur
block
glucosidas
caus
accumul
glycoprotein
glc
man
glcnac
structur
addit
compound
australin
especi
one
potent
activ
use
tool
help
understand
di
erenc
glucosidas
glucosidas
ii
inhibitor
anoth
interest
glucosidas
inhibitor
diamino
imino
b
glucopyranosyl
lycero
l
guloheptitol
mdl
compound
refer
follow
discuss
mdl
synthes
chemic
resembl
disaccharid
would
function
transit
state
analogu
intestin
enzym
sucras
anticip
mdl
inhibit
rat
intestin
maltas
sucras
isomaltas
glucoamylas
trehalas
present
micromolar
amount
interest
observ
mdl
also
show
specic
glucosidas
opposit
manner
australin
thu
mdl
much
e
ectiv
glucosidas
ii
glucosidas
cell
cultur
mdl
quit
di
erent
glucosidas
inhibitor
caus
accumul
glycoprotein
glc
man
glcnac
structur
howev
overal
e
ect
mdl
glycoprotein
function
cell
cultur
like
similar
observ
castanospermin
inhibitor
glucosidas
compound
name
trehazolin
isol
trehalas
inhibitor
also
test
inhibitor
process
glucosidas
compound
inhibit
glucosidas
quit
well
poor
inhibitor
glucosidas
ii
isol
demonstr
structur
like
australin
mdl
trehazolin
exist
compound
select
action
process
glucosidas
stimul
search
better
inhibitor
inhibitor
use
tool
addit
studi
role
carbohydr
especi
glucos
residu
function
local
n
link
glycoprotein
last
year
becom
clear
inhibitor
glucosidas
caus
mani
n
link
glycoprotein
accumul
er
heleniu
well
investig
elegantli
shown
er
protein
correct
fold
system
help
newli
synthes
er
protein
fold
proper
conform
necessari
transport
golgi
apparatu
system
involv
action
chaperon
e
protein
help
protein
fold
chaperon
name
calnexin
also
lectin
recogn
monoglucosyl
high
mannos
oligosaccharid
unfold
glycoprotein
presenc
castanospermin
glucosidas
inhibitor
rst
glucos
remov
therefor
unfold
protein
recogn
calnexin
help
fold
protein
fold
given
enough
time
fold
may
slow
interact
calnexin
help
speed
process
thu
protein
like
ldl
low
densiti
lipoprotein
receptor
insulin
receptor
antitrypsin
transport
golgi
much
slower
rate
presenc
glucosidas
inhibitor
inabl
calnexin
bind
protein
number
mannosidas
inhibitor
identi
natur
sourc
synthes
chemic
addit
use
tool
examin
role
mannos
oligosaccharid
function
n
link
glycoprotein
also
valuabl
distinguish
variou
mannosidas
activ
rst
glycoprotein
process
inhibitor
report
indolizidin
alkaloid
swain
sonin
inhibitor
mannosidas
ii
compound
initi
shown
inhibitor
lysosom
mannosidas
caus
symptom
lysosom
storag
diseas
mannosidosi
administ
anim
thu
swainsonin
essenti
prototyp
chemist
could
use
design
glycosidas
inhibitor
base
structur
swainsonin
castanospermin
deoxynojirimycin
appear
evid
use
glycosidas
inhibitor
follow
characterist
ring
structur
probabl
pyranos
type
nitrogen
replac
heterocycl
oxygen
ii
number
unknown
time
still
certain
hydroxyl
groupsand
iii
stereochemistri
hydroxyl
group
match
sugar
glycosidas
inhibit
specic
section
mannosidas
inhibitor
discuss
order
act
glycoprotein
process
pathway
figur
rather
order
histor
ident
base
fact
deoxynojirimycin
dnj
r
oh
good
inhibitor
glucosidas
reason
assum
relat
structur
mannos
chiral
would
inhibitor
mannosidas
epim
dnj
name
deoxymannojirimycin
dmj
r
b
oh
synthes
chemic
inde
found
potent
inhibitor
glycoprotein
process
mannosidas
interestingli
dmj
inhibit
jack
bean
lysosom
mannosidas
inhibit
mannosidas
ii
observ
select
specic
dmj
demonstr
danger
screen
new
glycosidas
inhibitor
use
commonli
occur
aryl
glycosidas
e
b
glucosidas
galactosidas
mannosidas
test
inhibitori
activ
goal
nd
new
glycoprotein
process
inhibitor
inhibitor
er
mannosidas
one
would
desir
specic
inhibitor
work
golgi
mannosidas
mannosidas
ii
jack
bean
lysosom
mannosidas
thu
one
use
enzym
hydrolyz
aryl
mannosid
p
manno
pyranosid
screen
compound
screen
would
obvious
neg
potenti
inhibitor
would
discard
period
sinc
deoxymannojirimycin
synthes
shown
specic
inhibitor
golgi
mannosidas
number
neutral
mannosidas
activ
report
anim
cell
enzym
discuss
section
glycoprotein
process
although
still
clear
role
play
trim
n
link
oligosaccharid
also
indic
earlier
enzym
di
erent
substrat
specic
mannosidas
thu
mani
resist
inhibit
dmj
new
man
nosidas
puri
separ
compet
activ
rapid
assay
measur
activ
becom
avail
easier
identifi
synthes
specic
new
inhibitor
enzym
nevertheless
time
number
mannosidas
inhibitor
identi
activ
variou
compound
di
erent
mannosidas
present
tabl
anim
cell
dmj
inhibit
golgi
mannosidas
ia
b
caus
accumul
glycoprotein
high
mannos
oligosaccharid
mostli
man
glcnac
structur
contrast
e
ect
glucos
analogu
dnj
prevent
secret
igd
igm
cell
cultur
dmj
e
ect
suggest
e
ect
dnj
due
function
calnexin
protein
fold
interact
glucos
howev
protein
fold
glucos
remov
protein
treat
normal
respect
target
regardless
whether
high
mannos
modi
chain
one
interest
studi
dmj
use
tool
determin
whether
glycoprotein
recycl
golgi
endocyt
process
experi
membran
glycoprotein
synthes
cho
cell
presenc
dmj
inhibit
mannos
trim
togeth
label
n
link
glycoprotein
appropri
incub
medium
chang
remov
inhibitor
label
cell
incub
addit
time
second
period
oligosaccharid
structur
transferrin
receptor
determin
condit
would
undergo
endocytosi
chase
oligosaccharid
structur
transferrin
receptor
high
mannos
type
chase
period
small
percentag
recycl
receptor
molecul
underw
process
gave
complex
type
structur
studi
indic
endocytos
glycoprotein
recycl
golgi
compart
may
undergo
oligosaccharid
process
howev
amount
glycoprotein
molecul
actual
modi
experi
small
indic
recycl
golgi
probabl
major
rout
ut
cell
use
examin
role
er
mannosidas
glycoprotein
target
function
ut
cell
cell
overexpress
hmg
coa
reductas
glycoprotein
enzym
resid
er
cell
oligosaccharid
chain
protein
high
mannos
type
mostli
man
glcnac
man
glcnac
structur
sinc
previou
studi
shown
er
mannosidas
inhibit
dmj
inhibitor
use
determin
whether
initi
trim
mannos
involv
er
mannosidas
studi
hmg
coa
reductas
produc
presenc
dmj
mostli
man
glcnac
structur
smaller
oligosaccharid
found
indic
er
enzym
involv
remov
rst
mannos
mannos
trim
dmj
sensit
mannosidas
dim
dideoxi
imino
mannitol
anoth
inhibitor
synthes
benzyl
mannopyranos
shown
good
inhibitor
jack
bean
mannosidas
also
inhibit
glycoprotein
process
cultur
mdck
cell
gave
rise
glycoprotein
mostli
man
glcnac
structur
suggest
inhibit
golgi
mannosidas
keep
observ
vitro
studi
partial
puri
prepar
mannosidas
show
dim
inhibit
releas
glcnac
howev
dim
nearli
e
ectiv
inhibitor
mannosidas
either
swainsonin
kifunensin
see
hand
dim
consider
interest
inhibitor
sinc
furanos
rather
pyranos
ring
structur
ii
synthes
chemic
therefor
produc
larg
amount
readili
modi
produc
variou
structur
analogu
clear
whether
compound
also
inhibit
er
mannosidas
sinc
activ
may
present
mdck
cell
kifunensin
alkaloid
produc
actinomycet
kitasatosporia
kifunens
correspond
structur
cyclic
oxamid
deriv
amino
dmj
alkaloid
weak
inhibitor
jack
bean
mannosidas
dmj
strong
inhibitor
golgi
mannosidas
ic
inhibit
almost
time
higher
inhibit
mannosidas
dmj
interestingli
kifunensin
e
ect
either
er
mannosidas
mannosidas
ii
inuenza
viru
infect
mdck
cell
incub
presenc
kifunensin
produc
inuenza
viru
particl
envelop
glycoprotein
n
link
oligosaccharid
mostli
man
glcnac
structur
e
ect
seen
presenc
dmj
howev
kifunensin
much
e
ectiv
caus
chang
structur
much
inhibitor
need
compar
dmj
compound
mimic
mannopyranosyl
cation
intermedi
propos
involv
enzymat
hydrolysi
mannopyranosid
synthes
chemic
name
mannonolactam
amidrazon
compound
inhibit
golgi
mannosidas
ic
mm
mannosidas
ii
ic
nm
also
potent
inhibitor
er
mannosidas
ic
mm
furthermor
compound
also
inhibit
aryl
mannosidas
ic
nm
aryl
b
mannosidas
ic
mm
although
clearli
prefer
linkag
cell
cultur
studi
mannonolactam
amidrazon
gave
rise
glycoprotein
type
high
mannos
oligosaccharid
seen
dmj
kifunensin
thu
inhibit
golgi
mannosidas
er
mannosidas
appear
prevent
trim
mannos
residu
design
compound
hypothes
reason
e
ectiv
gener
mannosidas
inhibitor
rst
analogu
mannos
mimic
true
half
chair
conform
cation
intermedi
believ
involv
catalysi
mannosid
mannonolactam
serv
model
synthesi
specic
mannosidas
inhibitor
mention
earlier
rst
process
inhibitor
describ
indolizidin
alkaloid
swainsonin
earli
studi
swainsonin
ad
cultur
media
mdck
cell
infect
inuenza
viru
cultur
label
addit
inhibitor
caus
signic
inhibit
amount
mannos
label
endo
h
resist
oligosaccharid
e
complex
oligosaccharid
great
increas
amount
mannos
label
endo
h
sensit
structur
latter
oligosaccharid
shown
hybrid
type
oligosaccharid
howev
chang
structur
viral
oligosaccharid
complex
hybrid
type
ect
product
matur
releas
inuenza
viru
particl
earli
studi
identifi
specic
site
swainsonin
inhibit
later
vitro
studi
puri
mannosidas
demonstr
swainsonin
specic
inhibit
mannosidas
ii
inact
toward
mannosidas
keep
site
action
swainsonin
caus
format
hybrid
structur
ad
medium
cultur
anim
cell
produc
vsv
glycoprotein
e
g
protein
bronectin
bhk
cell
surfac
glycoprotein
studi
swainsonin
use
determin
e
ect
chang
oligosaccharid
structur
glycoprotein
function
inhibitor
littl
e
ect
function
aspect
protein
question
although
caus
alter
structur
hybrid
chain
inhibitor
prevent
receptor
mediat
uptak
mannos
termin
glycoprotein
macrophag
inhibit
probabl
due
format
hybrid
structur
macrophag
surfac
could
react
bind
mannos
receptor
swainsonin
prove
valuabl
tool
determin
sequenc
addit
certain
sugar
assembl
n
link
oligosaccharid
thu
addit
l
fucos
sulfat
inuenza
viral
protein
studi
presenc
variou
process
inhibitor
glycoprotein
produc
presenc
castanospermin
dmj
associ
glycoprotein
suggest
fucos
sulfat
ad
mannosidas
step
process
howev
presenc
swainsonin
glycoprotein
contain
l
fucos
sulfat
indic
transferas
ad
group
work
glcnac
transferas
process
step
result
agre
report
acceptor
oligosaccharid
specic
e
glcnac
man
glcnac
fucosyltransferas
sulfotransferas
studi
swainsonin
caus
loss
function
specic
protein
thu
gluco
corticoid
stimul
resorpt
cell
involv
attach
osteoblast
bone
inhibit
swainsonin
treatment
either
parasit
trypanosoma
cruzi
macrophag
swainsonin
inhibit
interact
cell
alkaloid
also
caus
dramat
declin
abil
melanoma
cell
colon
lung
experiment
anim
result
similar
studi
swainsonin
undergo
test
consider
drug
treat
certain
type
cancer
mani
studi
done
interest
compound
mani
studi
summar
review
anoth
inhibitor
mannosidas
ii
name
mannostatin
isol
fungu
streptoverticillium
verticillu
compound
special
interest
unusu
structur
exocycl
nitrogen
member
ring
thiomethyl
group
still
glycosidas
inhibitor
mannostatin
found
potent
inhibitor
jack
bean
mannosidas
well
mannosidas
ii
ic
nm
cell
cultur
studi
mannostatin
caus
format
type
hybrid
oligosaccharid
form
presenc
swainsonin
interestingli
acetyl
amino
group
mannostatin
result
loss
mannosidas
activ
compound
function
advantag
swainsonin
inhibitor
consider
interest
sinc
add
great
deal
addit
structur
inform
understand
requir
necessari
compound
glycosidas
inhibitor
